Skip To Main Content
Oncodesign SA on Muck Rack

Oncodesign SA

As seen in: BMC Cancer
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Oncodesign SA’s profile

Articles by Oncodesign SA

BusinessWire - Oncodesign SA (A1107T) OFFRE PUBLIQUE D’ACHAT SIMPLIFIEE VISANT LES ACTIONS DE LA SOCIÉTÉ ONCODESIGN

|
By Oncodesign SA
| Research Pool
Regulatory News: Oncodesign (Paris:ALONC) : Oncodesign INITIÉE PAR Cancer Buster Bidco SAS Communiqué de mise à disposition du public de la note en réponse et du document « autres informations » relatif aux caractéristiques notamment juridiques, financières et comptables de la société Oncodesign (la « Société ») AMF | Autorité des Marchés Financiers Le présent communiqué a été établi par la société ONCODESIGN et diffusé en application des dispositions des articles 231-27 et 231-28 du...
Open in Who Shared Issue with article?

BusinessWire - Oncodesign SA (A1107T) L’Assemblée Générale d’Oncodesign autorise l’attribution des actions Oncodesign Precision Medicine (OPM) aux actionnaires d’Oncodesign

|
By Oncodesign SA
| Research Pool
A1107T Oncodesign SA L’Assemblée Générale d’Oncodesign autorise l’attribution des actions Oncodesign Precision Medicine (OPM) aux actionnaires d’Oncodesign Regulatory News: L’Assemblée Générale d’Oncodesign (Paris:ALONC) qui s’est tenue le 30 septembre 2022 a autorisé la distribution des actions OPM aux actionnaires Oncodesign. Chaque actionnaire d’Oncodesign recevra une action OPM pour une action Oncodesign détenue.
Open in Who Shared Issue with article?

BusinessWire - Oncodesign SA (A1107T) Euronext Paris autorise l’admission des actions Oncodesign Precision Medicine (OPM) sur Euronext Access + dans le cadre de l’attribution des actions OPM aux actionnaires d’Oncodesign

|
By Oncodesign SA
| Research Pool
Regulatory News: Oncodesign Precision Medicine (OPM), filiale d’Oncodesign (ALONC – FR0011766229) (Paris:ALONC) et Oncodesign annoncent qu’Euronext Paris S.A. a autorisé le 26 septembre 2022 l’admission à la cotation sur le marché Euronext Access + à Paris des actions ordinaires de la société OPM, selon la procédure de cotation directe dans le cadre de l’attribution d’actions OPM aux actionnaires d’Oncodesign.
Open in Who Shared Issue with article?

BusinessWire - Oncodesign SA (A1107T) Oncodesign annonce ses résultats du 1er semestre 2022 : croissance de 28% du chiffre d’affaires de Service

|
By Oncodesign SA
| Research Pool
Regulatory News: ONCODESIGN (ALONC – FR0011766229), groupe biopharmaceutique spécialisé en médecine de précision, annonce ses résultats du premier semestre 2022.
Open in Who Shared Issue with article?

BusinessWire - Oncodesign SA (A1107T) Oncodesign poursuit sa croissance avec une forte augmentation de son chiffre d’affaires Service au 1er semestre 2022

|
By Oncodesign SA
| Research Pool
Regulatory News: ONCODESIGN (ALONC – FR0011766229) (Paris:ALONC), groupe biopharmaceutique spécialisé en médecine de précision, annonce ses revenus et produits d’exploitation du 1er semestre 2022.
Open in Who Shared Issue with article?

BusinessWire - Oncodesign SA (A1107T) ONCODESIGN: Suspension de cotation dans l’attente d’un communiqué

|
By Oncodesign SA
| Research Pool
DIJON, France--(BUSINESS WIRE)-- Regulatory News: ONCODESIGN (FR0011766229 - ALONC) (Paris:ALONC), groupe biopharmaceutique spécialisé en médecine de précision, a demandé à Euronext de suspendre la cotation de son titre (FR0011766229 – ALONC) admis sur le marché Euronext Growth à compter de l’ouverture du marché ce jour, dans l’attente d’un communiqué de presse. Consultez la version source sur businesswire.com :
Open in Who Shared Issue with article?

OncoSNIPE® Study Protocol, a study of molecular profiles associated with development of resistance in solid cancer patients - BMC Cancer

|
By Sarah El, Oncodesign SA, Dijon Cedex, Institut Paoli-Calmettes
| BMC Cancer Verified
Study population Adult patients with a diagnosed triple negative or Luminal B breast cancer, locally advanced or metastatic non-small-cell lung cancer or PDAC and managed at Georges-François Leclerc Cancer Center (Dijon), Curie Institute (Paris), Paoli Calmettes Institute (Marseille), Haute-Pierre Hospital (Strasbourg), Godinot Institute (Reims), Léon Bérard Center (Lyon), Lorraine Cancer Institute (Nancy), APHP-Beaujon Hospital (Clichy), F-Mitterand Dijon-Bourgogne University Hospital Center...
Open in Who Shared Issue with article?

Oncodesign SA (ALONC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile [Updated: 12-05-2017]

|
By Oncodesign SA
| bioportfolio.co.uk
Oncodesign SA (Oncodesign) is a biotechnology company that offers drug discovery and pharmacological evaluation services for cancer. The company offers a wide range of products and services for the validation, assessment, targeting and diagnostic linking of anti-cancer therapies based on its technological platforms.
Open in Who Shared Issue with article?

Oncodesign SA (ALONC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile [Updated: 21-02-2017]

|
By Oncodesign SA
| bioportfolio.co.uk
Oncodesign SA (Oncodesign) is a biotechnology company that offers drug discovery and pharmacological evaluation services for cancer. The company offers a wide range of products and services for the validation, assessment, targeting and diagnostic linking of anti-cancer therapies based on its technological platforms.
Open in Who Shared Issue with article?

Oncodesign SA (ALONC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

|
By Oncodesign SA
| bioportfolio.co.uk
Oncodesign SA (Oncodesign) is a biotechnology company that offers drug discovery and pharmacological evaluation services for cancer. The company offers a wide range of products and services for the validation, assessment, targeting and diagnostic linking of anti-cancer therapies based on its technological platforms.
Open in Who Shared Issue with article?
Show More